Skip to main content
Premium Trial:

Request an Annual Quote

CMS Issues Final Payment Decision for Exact Sciences' Cologuard Test

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services has issued its final payment decision for Exact Sciences' Cologuard test and will reimburse providers $502 per test, the firm announced today.

It is the exact reimbursement price the Madison, Wis.-based molecular diagnostics firm had proposed to CMS, discounted from the list price of $600.

The noninvasive colorectal cancer test is the first and only US Food and Drug Administration-approved test screening DNA from stool samples, the firm said in a statement.

In August, the Mayo Clinic became the first healthcare system to offer the test, and on Nov. 6, the American Cancer Society updated its national guidelines on colorectal cancer prevention and early detection to reflect the commercial availability of the test. 

The final payment decision follows an evaluation by the agency as part of a joint FDA and CMS parallel review program. Cologuard is the first technology to gain approval through this program.

In Tuesday afternoon trade on the Nasdaq, shares of Exact Sciences were up around 3 percent at $25.08.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.